Bavarian Nordic Announces Interim Results for the First Three Months of 2025

Core Insights - Bavarian Nordic A/S reported a strong performance in Q1 2025, with revenue increasing by 62% year-over-year to DKK 1,347 million, driven by growth in both Travel Health and Public Preparedness segments [2][7] - The company achieved an EBITDA margin of 31%, significantly up from 3% in the same quarter of 2024, and maintains its full-year revenue guidance of DKK 5,700-6,700 million with an EBITDA margin of 26-30% [2][7] Travel Health - Travel Health revenue rose by 52% to DKK 680 million, primarily due to increased demand for rabies and tick-borne encephalitis (TBE) vaccines [7] - The company is ahead of its strategic goal of achieving an average annual growth rate of 10-12% in this segment until 2027 [2] Public Preparedness - Public Preparedness revenue surged by 83% to DKK 629 million, exceeding expectations due to the advancement of larger existing orders into Q1 [7] - The FDA approved the freeze-dried version of the JYNNEOS vaccine for smallpox and mpox, supporting ongoing contracts with the US government for stockpiling [4] New Product Developments - The chikungunya vaccine, Vimkunya, was approved in the US and EU, with commercial launch in the US occurring in March 2025 and plans for European markets in the first half of 2025 [8][13] - A strategic partnership was established with Biological E. Limited to enhance vaccine access in low- and middle-income countries [8] Financial Activities - In January 2025, Bavarian Nordic completed a share buy-back program worth DKK 150 million to adjust its capital structure [5]